Abstract
The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.
Keywords: Ran GTPase, Ranbp1, Ranbp2, Ranbp9, Ranbp10, c-met, nucleo-cytoplasmic transport, macromolecules, anthologies, mitosis, cancer, oncogenic pathway, metastasis, microtubule-interacting drugs, chemotherapy
Current Molecular Medicine
Title: RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins
Volume: 11 Issue: 8
Author(s): K. J. Doherty, C. McKay, K. K. Chan and M. K. El-Tanani
Affiliation:
Keywords: Ran GTPase, Ranbp1, Ranbp2, Ranbp9, Ranbp10, c-met, nucleo-cytoplasmic transport, macromolecules, anthologies, mitosis, cancer, oncogenic pathway, metastasis, microtubule-interacting drugs, chemotherapy
Abstract: The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.
Export Options
About this article
Cite this article as:
J. Doherty K., McKay C., K. Chan K. and K. El-Tanani M., RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins, Current Molecular Medicine 2011; 11 (8) . https://dx.doi.org/10.2174/156652411797536688
DOI https://dx.doi.org/10.2174/156652411797536688 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomedicine to Overcome Cancer Multidrug Resistance
Current Drug Metabolism Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists
Recent Patents on Anti-Cancer Drug Discovery Proteomic Profiling of a Biomimetic Drug Delivery Platform
Current Drug Targets Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1<sup>®</sup> can Overcome Drug Resistance in Osteosarcoma
Current Cancer Drug Targets Electron Spin Resonance as a Powerful Tool for Studying Antioxidants and Radicals
Current Medicinal Chemistry Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells
Current Medicinal Chemistry Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Regulation of HIPK Proteins by MicroRNAs
MicroRNA Recent Advances in Radiation Therapy of Cancer Cells: A Step towards an Experimental and Systems Biology Framework
Current Radiopharmaceuticals Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Antiproliferative and Antifungal Activities of 1,3-diarylpropane-1,3-diones Commonly used as Sunscreen Agents
Letters in Drug Design & Discovery Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene
Current Drug Metabolism Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy